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Management of hyperkalemia in the acutely 
ill patient
François Dépret1,2,3, W. Frank Peacock5, Kathleen D. Liu6, Zubaid Rafique5, Patrick Rossignol4,7  
and Matthieu Legrand1,2,3,4*
Abstract 
Purpose: To review the mechanisms of action, expected efficacy and side effects of strategies to control hyper-
kalemia in acutely ill patients.
Methods: We searched MEDLINE and EMBASE for relevant papers published in English between Jan 1, 1938, and July 
1, 2018, in accordance with the PRISMA Statement using the following terms: “hyperkalemia,” “intensive care,” “acute 
kidney injury,” “acute kidney failure,” “hyperkalemia treatment,” “renal replacement therapy,” “dialysis,” “sodium bicarbo-
nate,” “emergency,” “acute.” Reports from within the past 10 years were selected preferentially, together with highly 
relevant older publications.
Results: Hyperkalemia is a potentially life-threatening electrolyte abnormality and may cause cardiac electrophysi-
ological disturbances in the acutely ill patient. Frequently used therapies for hyperkalemia may, however, also be 
associated with morbidity. Therapeutics may include the simultaneous administration of insulin and glucose (associ-
ated with frequent dysglycemic complications), β-2 agonists (associated with potential cardiac ischemia and arrhyth-
mias), hypertonic sodium bicarbonate infusion in the acidotic patient (representing a large hypertonic sodium load) 
and renal replacement therapy (effective but invasive). Potassium-lowering drugs can cause rapid decrease in serum 
potassium level leading to cardiac hyperexcitability and rhythm disorders.
Conclusions: Treatment of hyperkalemia should not only focus on the ability of specific therapies to lower serum 
potassium level but also on their potential side effects. Tailoring treatment to the patient condition and situation may 
limit the risks.
Keywords: Hyperkalemia, Intensive care, Emergency, Renal replacement therapy, Acute kidney injury
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Background
Hyperkalemia is a potentially life-threatening electro-
lyte abnormality [1–3]. Although there is no interna-
tionally agreed upon definition for hyperkalemia, the 
European Resuscitation Council defines hyperkalemia 
as a plasma level > 5.5  mmol/L and severe hyperkalemia 
as > 6.5  mmol/L [4]. Hyperkalemia is associated with 
poor outcomes in many different settings, including the 
acutely ill patient [5, 6]. In acute hyperkalemia, the pri-
mary mortality risks are cardiac rhythm or conduction 
abnormalities [7, 8]. However, the actual causes of death 
in patients with hyperkalemia are poorly described, and 
the causal relationship between hyperkalemia and out-
come remains controversial.
The aim of this review is first to describe mecha-
nisms and the risk–benefit ratio of different strategies 
of hyperkalemia treatment and second, to propose a 
tailored treatment strategy. This will include a discus-
sion of the effectiveness as well as complications of renal 
replacement therapy, limiting the risk of hypoglycemia 
with judicious insulin and glucose administration, and 
the potential benefit and risks of hypertonic sodium 
bicarbonate.
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Methods
We searched MEDLINE and EMBASE for relevant 
papers published in English between Jan 1, 1938, and 
July 1, 2018, in accordance with the PRISMA State-
ment using the following terms: “hyperkalemia,” “inten-
sive care,” “acute kidney injury,” “acute kidney failure,” 
“hyperkalemia treatment,” “renal replacement therapy,” 
“dialysis,” “sodium bicarbonate,” “emergency,” “acute.” 
Reports from within the past 10  years were selected 
preferentially together with highly relevant older 
publications.
Association between hyperkalemia and outcomes
The potassium ion  (K+) is the most abundant cation in 
the body. There is an estimated total reserve of 3000–
4000 mmol in adults, of which only 60 mmol (2%) are 
extracellular [9]. Hyperkalemia is associated with poor 
outcomes in many different settings: in the general 
population [5, 6], in patients with cardiac and renal 
disease [10–13] and in critically ill patients [14]. In a 
retrospective study of hospitalized patients, Khana-
gavi et al. [5] found that acute kidney injury (AKI) and 
prolonged hyperkalemia are independent predictors of 
in-hospital mortality. In acute myocardial infarction, a 
serum potassium above 4.5 mmol/L is associated with a 
higher mortality [11]. More recently, Legrand et al. [15] 
identified that a serum potassium > 4.5 mmol/L in heart 
failure patients admitted to the emergency department 
(ED) is associated with an increased risk of death.
The net effect is a U-shaped mortality curve associ-
ated with potassium abnormalities [16–19]. Several 
observational studies have identified hypokalemia as an 
independent risk factor for poor outcome [13, 16–19]. 
This association raises concern regarding the potential 
for overcorrection, as may occur with some fast-acting 
potassium-lowering agents. However, these associa-
tions do not mean causality and thresholds for treating 
hyperkalemia remain debated.
Cardiac manifestations of hyperkalaemia
Although patients with hyperkalemia can present rarely 
with weakness progressing to flaccid paralysis, pares-
thesias, or depressed deep tendon reflexes, the clinical 
presentation of hyperkalemia is usually benign until 
cardiac rhythm or conduction disorders occur. Eleva-
tion of extracellular potassium has several effects on 
myocardial electrophysiology that contribute to intra-
cardiac conduction disturbances. The intracellular to 
extracellular potassium gradient lessens when extracel-
lular potassium increases, thus decreasing the resting 
membrane potential. Elevated extracellular potassium 
also increases membrane permeability for potassium, 
lowers membrane resistance, increases repolarizing 
currents, and shortens transmembrane action potential 
duration.
While rising serum potassium initially increases con-
duction velocity, it decreases it at higher levels [20]. Clas-
sic hyperkalemia electrocardiographic findings include 
signs of hyperexcitability such as peaked T-waves (reflect-
ing a decrease in the threshold for rapid depolarization). 
Further, altered conduction may manifest as PR prolon-
gation, loss of P-waves, QRS widening, bradycardia, and 
ultimately a sine wave rhythm due to action potential 
shortening and prolongation of diastolic depolarization.
Importantly, the correlation between potassium eleva-
tion and electrocardiographic (ECG) changes is poor. 
Severe hyperkalemia may manifest with minimal or 
atypical ECG findings [1–3, 21], including nonspecific 
ST segment modification or pseudo-Brugada syndrome 
(featuring wide QRS, elevation of the ST segment, J-point 
elevation, T-wave inversion). On the contrary moderate 
hyperkalemia (< 6  mmol/L) may have life-threatening 
ECG findings. The electrocardiographic manifestations 
of hyperkalemia are largely influenced by rapid changes 
of plasma concentration [7], the gradient of potassium 
across the myocardial cell membrane, the effect of other 
ions (i.e., sodium, calcium), as well as underlying cardiac 
disease [22]. Retrospective data found a higher mortal-
ity rate in patients with hyperkalemia showing abnormal 
ECG findings [23]. Along these lines, chronically dialyzed 
patients may show no ECG signs of hyperkalemia despite 
high serum potassium levels. Altogether, more than the 
absolute serum potassium level, therapeutic strategies 
should be guided by the cardiac consequences of hyper-
kalemia identified on the ECG (Fig. 1).
Causes of hyperkalemia in acutely ill patients
Factors associated with the development of hyperkalemia 
can be classified into three categories, and include altered 
renal clearance of potassium (e.g., chronic kidney disease, 
acute kidney injury, renin–angiotensin–aldosterone sys-
tem inhibitor), release from the intracellular space (e.g., 
hemolysis, rhabdomyolysis, tissue injury) and altered 
transfer to the intracellular space (e.g., acidosis, insulin 
deficit, β-adrenergic blockers, heparin) (Table 1). Hyper-
kalemia in the patient with normal renal function is 
unusual and should prompt evaluation for pseudo-hyper-
kalemia if no ECG abnormalities consistent with hyper-
kalemia are identified (false elevation of potassium due to 
hemolysis occurring with blood draw and not reflective 
of the patient’s plasma potassium concentration). While 
concomitant medications (e.g., potassium supplements, 
penicillin G, digoxin, nonsteroidal anti-inflammatory 
drugs, renin–angiotensin–aldosterone system inhibitor, 
amiloride, triamterene, trimethoprim, pentamidine) are 
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often a contributor to hyperkalemia, in our experience 
they are rarely the only cause in acute settings.
Since the potassium pool is mostly intracellular, altera-
tion of cellular potassium uptake can be a major con-
tributors to hyperkalemia [24]. Hyperchloremic acidosis 
is frequent in acutely ill patients [25]. According to the 
Stewart’s theory, the main determinant of acid–base 
balance is the strong ion difference (SID), essentially 
determined by the difference between the strong cation 
(sodium) and the anions (chloride) [26]. A possible mech-
anism to explain hyperkalemia related to hyperchloremic 
acidosis is that mineral acids (i.e., chloric) cannot freely 
diffuse into the intracellular compartment, they decrease 
extracellular pH. Low extracellular pH decreases the 
 Na+–H+ exchange and inhibits the inward movement 
of  Na+. The subsequent fall in intracellular  Na+ reduces 
 Na+–K+-ATPase activity, leading to a net decrease in  K+ 
transfer into the cell and higher extracellular potassium 
levels. In this line, utilization of balanced solutions with 
physiological concentrations of chloride (i.e., Ringers 
lactate) prevents the development of mineral metabolic 
acidosis and is associated with lower serum potassium 
levels compared to NaCl 0.9% [25, 27, 28]. The effect of 
metabolic acidosis appears less prominent when organic 
acids accumulate (i.e., lactate, phosphate). This is because 
organic acids can passively diffuse into the intracellular 
compartment, resulting in a larger fall in intracellular pH. 
The fall of intracellular pH stimulates inward  Na+ move-
ment and maintains  Na+–K+-ATPase activity, which 
minimizes the extracellular accumulation of potassium 
[29]. Ultimately, the increased intracellular  Na+ concen-
tration leads to the intracellular entry of potassium [29].
A special warning should be made with regards to the 
use of succinylcholine, classically used to induce paralysis 
Fig. 1 Suggested algorithm for hyperkalemia treatment in the acutely ill. *In case of Digitalis intoxication or hypercalcemia. **Sodium zirconium 
cyclosilicate and patiromer when available, kayexalate if not available. ESKD end-stage kidney disease, AKI acute kidney injury, CKD chronic kidney 
disease, RRT renal replacement therapy
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in acutely ill patients for rapid sequence intubation. 
Succinylcholine induces skeletal muscle cell depolari-
zation with an efflux of intracellular potassium by nico-
tinic receptor activation. In a population of critically ill 
patients, succinylcholine increased serum potassium on 
average 0.4  mmol/L (interquartile range 0–0.7  mmol/L) 
[30]. It should be avoided in patients with hyperkalemia 
and in patients with up-regulation of nicotinic receptors, 
as they are at risk of greater potassium elevation. This 
includes those with anatomical denervation, prolonged 
administration of neuromuscular blocking drugs, burn 
injury, and prolonged immobilization [31]. Alternative to 
succinylcholine are available in patients at risk of hyper-
kalemia (i.e., rocuronium).
Medical strategy
First‑line treatment in hyperkalemia with ECG 
abnormalities: myocardial protection
Calcium salt
The intravenous administration of a calcium salt 
increases the cardiac threshold potential, the speed of 
impulse propagation and stabilizes the myocellular mem-
brane, thus causing almost immediate normalization of 
the ECG abnormalities (Fig. 2). In 1950, Merrill et al. [32] 
found a beneficial effect of intravenous calcium salt in 9 
of 10 patients with hyperkalemia. Four years later, this 
was confirmed by Chamberlain et al. [33], who reported 
five cases of an immediate effect of intravenous calcium 
on ECG changes induced by severe hyperkalemia (from 
8.6 to 10  mmol/L). There are no randomized studies to 
show its efficacy and its indications are based on expert 
opinion [34]. The effect should be immediate (within 
5 min) when any hyperkalemia-related ECG changes are 
identified or suspected [33]. The protective effect may 
last between 30 and 60  min [35]. Calcium administra-
tion in the case of hypercalcemia may be problematic. 
It also increased toxicity with digoxin overdose in ani-
mal models [34]. However, this effect was found only at 
nonphysiologically high calcium concentrations [35]. The 
use of calcium in cases of hyperkalemia associated with 
digoxin toxicity was not associated with life-threatening 
dysrhythmias or mortality in human studies [36–38]. 
Finally, calcium may cause tissue injury (i.e., skin necro-
sis) in case of extravasation [39]. The recommended dose 
is 10–20 mL of a 10% calcium salt (e.g., 1–2 g of gluco-
nate or chloride).
Hypertonic sodium
Infusion of hypertonic sodium also increases the action 
potential rising velocity in isolated cardiomyocytes [42]. 
In 1960, Greenstein et al. [43] studied the effect of sodium 
lactate, sodium bicarbonate, and sodium chloride on 
ECG abnormalities induced by hyperkalemia in nephrec-
tomized dogs. Infusion of hypertonic sodium increased 
the action potential rising velocity, which was depressed 
when isolated cardiomyocytes were exposed to increas-
ing concentrations of potassium [42]. Taken together, 
these results suggest that hypertonic sodium acts as a 
membrane stabilizer and might be considered as an alter-
native to calcium in hyperkalemia-induced ECG changes 
when infusion of calcium is at risk. Furthermore, the 
fluid loading associated with hypertonic sodium bicarbo-
nate may increase the glomerular filtration rate and renal 
potassium excretion in volume-depleted patients.
Intracellular potassium transfer
Hypertonic sodium bicarbonate
Although the data supporting the use of sodium bicar-
bonate as a treatment for hyperkalemia are contro-
versial, it does have effects on serum potassium after 
infusion of hypertonic sodium bicarbonate. Some 
reported little effect on the potassium concentration 
in stable hemodialysis patients [44, 45]. In 1997, Ngugi 
et  al. [46] observed that bicarbonate was less effective 
than salbutamol and insulin–dextrose in groups of 10 
patients with end-stage renal disease (i.e., not acutely 
ill). Others reported effects on serum potassium. 
Schwarz et  al. [47] reported that an infusion of 144–
408  mmol of sodium bicarbonate over 2–4  h lowered 
the serum potassium by 2–3  mmol/L in four patients 
with severe acidosis.
In a recent randomized controlled trial (RCT), hyper-
tonic sodium bicarbonate (4.2%) was administered to 
Table 1 Mechanisms contributing to  the  development 
of hyperkalemia
K+ potassium, RAAS renin–angiotensin–aldosterone system
Mechanisms contributing to the development of hyperkalemia
Increased extracellular  K+ Decreased  K+ elimination
Tissue injury
 Hemolysis
 Rhabdomyolysis
 Tumor lysis syndrome
K+ shift in extracellular space
 Mineral acidosis (i.e., hyperchoride 
acidosis)
 Succinylcholine
Inability to enter into myocyte
 Diabetes mellitus
 Hyperglycemia
 Hypertonicity
 β2-receptor antagonists
 Aldosterone blockers
 Cardiac glycosides
High acute iatrogenic  K+ load
 Increased dietary intake
 Blood transfusion
 Error of injection
AKI
 Hypovolemia
 Sepsis
Acidosis treatment
 RAAS inhibitor
 Calcineurine inhibitor
 Cardiac glycosides
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critically ill patients with severe metabolic acidaemia 
(pH < 7.2) [48]. There was no difference in the primary 
outcome (composite of death from any cause by day 28 
or 1 organ failure at day 7), but the sodium bicarbonate 
group had significantly lower potassium concentra-
tions compared to the control group and required renal 
replacement therapy less frequently. A more recent retro-
spective study also reported improved survival in septic 
patients with AKI stage 2 or 3 and severe acidosis treated 
with sodium bicarbonates infusion [49]. However, the 
impact on serum potassium was not reported.
Metabolic alkalosis, hypernatremia, hypocalcemia, 
and fluid overload are potential expected side effects of 
sodium bicarbonate (Table 2). Hypertonic sodium bicar-
bonate can cause hypocalcaemia in a pH dependent 
manner and by direct calcium binding [50]. In the Jaber 
et al. [48] study, more patients in the bicarbonate group 
had ionized calcium lower than 0.9  mmol/L compared 
to patients in the placebo group (24% vs 15%, p = 0.0167) 
and 2 patients had a ionized calcium below 0.5 mmol/L in 
the bicarbonates group versus none in the placebo group. 
Calcium is key for cardiac contractility. In an experimen-
tal model of lactic acidosis, Kimmoun et al. [51] reported 
improved myocardial elastance, aortic and mesenteric 
vasoreactivity when sodium bicarbonate was combined 
with calcium compared to sodium bicarbonate alone. 
Severe hypocalcemia can cause myocardial dysfunction 
and therefore ionized calcium should be monitored and 
ionized hypocalcemia corrected after sodium bicarbo-
nate infusion. Finally, even though sodium bicarbonate 
has been suspected of causing intracellular acidosis, this 
has not been confirmed in  vivo [52]. We therefore rec-
ommend to use hypertonic sodium bicarbonate (e.g., 
100–250  mL of 8.4% sodium bicarbonate over 20  min) 
in patients with metabolic acidosis (pH < 7.2) or in 
patients with a contraindication to calcium administra-
tion (patients with hypercalcemia and/or severe digoxin 
intoxication), whether sodium bicarbonate is efficient in 
reducing serum potassium in patients without severe aci-
dosis and the impact of the mechanism of metabolic aci-
dosis need further exploration.
Insulin–dextrose
Insulin binds to the insulin receptor on skeletal mus-
cle, activates the sodium–potassium adenosine triphos-
phatase, and leads to potassium transfer from the 
extracellular to intracellular space (Fig. 3) [53]. Although 
insulin–dextrose has never been tested versus placebo 
for the treatment of hyperkalemia, it shows similar 
effects on serum potassium compared with salbutamol 
in a study of 20 patients [46, 54] but with faster decrease 
in serum potassium with insulin (i.e., 15 vs 30  min). 
Of note, combination of both further lowered serum 
potassium compared to separate treatments. The major 
side effect of insulin is hypoglycemia, which has been 
reported to occur up to 75% in subjects, depending of the 
protocol  [55, 56]. One of the few blinded ED studies of 
hyperkalemia management found a 17% rate of clinically 
significant hypoglycemia after insulin–dextrose therapy 
[53].
Several studies suggest that a lower bolus dose of 
insulin may be safer. In 2 retrospective studies, similar 
potassium-lowering effects were found with the admin-
istration of either 5 or 10 U of insulin (and 25 g of dex-
trose), but a higher incidence of hypoglycemia occurred 
with the higher insulin dose [57, 58]. To limit hypogly-
cemia with the 10 U insulin dose required using 50 g to 
60  g of dextrose [59]. Another strategy is to administer 
weight-based insulin dosing (0.1 U/kg of body weight up 
to a maximum of 10 U) to limit episodes of hypoglycemia 
without impacting potassium lowering [60]. Finally, using 
an infusion limited to 30 min led to a faster decrease in 
potassium, but less hypoglycemia as compared to con-
tinuous infusion [61]. Ultimately, because of the risk of 
hypoglycemia, blood glucose should be measured on an 
hourly basis for at least 2 h, and potentially longer in the 
setting of renal failure [61]. While the risks of hypogly-
cemia have long been recognized, the risk of hyperglyce-
mia is probably underappreciated. To summarize, using 
5 U of insulin with 25 g of dextrose appears an effective 
and safe regimen. The impact of exogenous administra-
tion of insulin and glucose on serum potassium and 
organ damage in this setting is unknown. Intravenous 
administration of high doses of glucose to limit the risk 
Fig. 2 Cardiac effect of hypertonic sodium and calcium salt during hyperkalemia. During hyperkalemia, resting membrane potential increases, 
derecruiting the sodium voltage gate channel Nav1.5 (left panel). Calcium salts bind to calcium-dependent calmodulin and protein kinase II 
(CaMKII) and activates the sodium voltage gate channel leading to an intracellular sodium entrance (right panel). Calcium salt restores the channel 
activity though the calcium-dependent calmodulin (CaM), recruiting the voltage-gated channel Nav1.5, increasing the intracellular sodium 
entrance, restore dV/dt phase 0 action potential and increase in the resting membrane potential. Hypertonic sodium increases extracellular sodium 
concentration and “forces” intracellular sodium entrance (right panel). The bottom panel represents on the left the decrease of dV/dt phase 0 action 
potential due to hyperkalemia (Bottom left panel), restored by either calcium or hypertonic sodium (Bottom rightpanel)(Adapted from [40, 41] with 
authorization)
(See figure on next page.)
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of hypoglycemia may induce severe hyperglycemia, 
which has been associated with organ damage, vascu-
lar dysfunction and poor outcomes in different settings 
(i.e., heart failure, sepsis, critically ill patients) [62–64]. 
Critically ill patients often present with hyperglycemia 
and insulin resistance. We propose insulin–glucose as 
first-line treatment in patients with relative contraindi-
cation to β-2 agonists (Table 2) and patients with severe 
hyperkalemia (i.e.,  ≥ 6.0 mmol/L or associated with ECG 
changes).
Fig. 3 Action mechanisms of plasma lowering treatments by intracellular transfer. β-2 agonist (i.e., salbutamol) binds the β-2 receptor, insulin binds 
insulin receptors and sodium bicarbonate  (NaHCO3) induces an intracellular entrance of sodium through the  Na
+/H+ exchanger (NHE), all activate 
the sodium–potassium adenosine triphosphatase  (NaK+ ATPase) leading to a potassium transfer from the extracellular space to the intracellular 
space
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β‑2 agonists
Salbutamol (e.g., albuterol) is effective at lowering potas-
sium, without differences between nebulized or intrave-
nous administration, in terms of its efficacy [65, 66] even 
though effectiveness appears variable. However, salbuta-
mol administered intravenously is associated with more 
cardiovascular side effects than the nebulized route [67]. 
In one study of 10 patients treated with 10–20 mg salbu-
tamol, the maximal decrease in potassium ranged from 
0.4 to 1.22  mmol/L [65, 66]. The peak effect occurred 
between 60 and 90  min after administration, and the 
higher salbutamol dose was more efficient in lowering 
potassium. Due to systemic effects of salbutamol, regard-
less of the route of administration, side effects, such as 
tachycardia may also be of concern in patients with heart 
failure or unstable angina. Finally, other consequences 
of β-2-agonists are hyperglycemia and increased plasma 
lactate. Impacts of treatments with β-blockers or efficacy 
in critically ill patients remain unexplored. Critically ill 
patients may present sympatho-adrenal activation (i.e., 
with tachycardia, vasoconstriction, hyperglycemia). We 
recommend the utilization of 10  mg nebulized salbuta-
mol as first-line therapy in nonsevere hyperkalemia in 
spontaneous breathing patients without tachycardia.
Increase potassium urinary excretion
Loop diuretics inhibit the NKCC2 channel at the apical 
surface of thick ascending limb cells along the loop of 
Henle. NKCC2 is a sodium–potassium–chloride cotrans-
porter that reabsorbs (directly and indirectly) up to 25% 
of filtered sodium and chloride. Its blockade is respon-
sible for most natriuretic effects of loop diuretics [68]. 
Loop diuretic administration via the intravenous route 
is quickly followed by a similar dose dependent increase 
in both 24-h kaliuresis and natriuresis [69, 70]. The kaliu-
retic effect is predominately a function of an increased 
tubular flow rate and a higher sodium concentration in 
the late nephron, both leading to an induction of the Na/
K+-ATPase that increases potassium excretion in the dis-
tal tubules and collecting duct [70]. However, one major 
drawback of diuretics is the unpredictable natriuretic 
and kaliuretic effects, especially in patients with AKI or 
heart failure. These patients may be resistant to the diu-
retic and kaliuretic effects of diuretics, thus making this 
a poor strategy to control severe hyperkalemia. A “furo-
semide stress test” has been proposed in AKI patients 
to predict sustained AKI, with nonresponders defined 
as a urine output < 200 mL in the first 2 h after an infu-
sion of 1.0 or 1.5  mg/kg of furosemide [71]. In these 
nonresponders, alternative strategies to control hyper-
kalemia should not be delayed. Furthermore, loop diuret-
ics should be titrated (0.2–0.4 mg/kg in patient without 
AKI to 1–1.5 mg/kg of furosemide in patients with AKI) 
and only considered in patients with fluid overload after 
excluding low intravascular volume and with close atten-
tion to the amount of diuresis to avoid additional kidney 
insults resulting from iatrogenic hypovolemia. Finally, 
close monitoring for potential side effects, including 
the risk of secondary hypovolemia and other electro-
lytes disturbances (i.e., dysnatremia, metabolic alkalosis, 
hypophosphatemia, hypomagnesaemia) is needed. To 
conclude, except in patients with symptomatic fluid over-
load, diuretics should not be considered as a therapy for 
hyperkalemia.
Gastro intestinal excretion
Sodium polystyrene sulfonate (SPS)
SPS exchanges sodium for calcium, ammonium, and 
magnesium in addition to potassium in the colon (Addi-
tional file  1: Figure S1) [72]. To date, no controlled tri-
als in humans or animals have demonstrated that SPS 
increases fecal potassium losses, and no studies on the 
efficacy of SPS are available in the acute setting. How-
ever, serious gastrointestinal complications related to 
SPS, and attributed to sorbitol (co-administered with SPS 
to increase its delivery to the colon) have been described 
[73]. These include intestinal perforations, especially in 
patients with abnormal transit (e.g., patients in shock or 
who are immediately postoperative). Furthermore, its use 
has been associated with edema and increases in blood 
pressure-likely related to the fact that it exchanges potas-
sium for sodium. Due to its route of administration, its 
delayed and highly variable onset, and the potential for 
serious adverse side effects [35, 73], SPS is not a treat-
ment of choice in the acutely ill patient.
Emerging treatment alternatives
Patiromer
Patiromer is a sodium-free, nonabsorbed, potassium-
binding polymer, approved in the USAUS and in the 
European union (EU) for management of hyperkalemia. 
In a recent meta-analysis of phase 2 and phase 3 trials, 
it was associated with a decrease in serum potassium of 
0.21 ± 0.07 mmol/L within 7 h [74, 75]. Its long term effi-
cacy and safety was also shown in a 52-week trial [76]. 
Side effects include minor gastrointestinal intolerance 
and hypomagnesemia (7.1%) and edema due to exchange 
of potassium for sodium [75]. Patiromer has not been 
clinically tested in the emergency setting. Whether this 
compound may enable the maintenance of normoka-
lemia in emergency room patients is currently being 
tested (REDUCE study NCT: 02933450).
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Sodium zirconium cyclosilicate (ZS‑9)
ZS-9 is a crystal that is highly selective for potassium 
and ammonium ions exchanging sodium for potas-
sium [77]. A recent meta-analysis of phase 2 and phase 
3 studies concluded that ZS-9 was effective in main-
taining normokalemia with minor gastrointestinal side 
effects and edema [75]. Even though ZS-9 has not been 
specifically compared to existing alternatives for treat-
ment of severe hyperkalemia in emergency conditions, 
Kosiborod et  al. [78] recently described a subgroup 
of 45 patients with severe hyperkalemia (> 6  mmol/L) 
who received a 10 g dose of ZS-9. The median time to a 
serum potassium level < 6.0  mmol/L was 1.1  h, and the 
median time to a level ≤ 5.5 mmol/L was 4.0 h, suggesting 
that this treatment might be considered in severe acute 
hyperkalemia in patients with preserved gastrointesti-
nal function. However, because of the lack of data in the 
acute setting and its potential delayed onset of action, it 
was not approved for acute hyperkalemia management 
in either the US or in UE. An ongoing phase 2 study 
(NCT03337477) is evaluating the short term efficiency of 
ZS-9 plus insulin–dextrose versus insulin–dextrose alone 
in patients with acute hyperkalemia.
Renal replacement therapy
Indication of Renal replacement therapy
Severe hyperkalaemia is a key indication for renal 
replacement therapy (RRT) (e.g., hemodialysis or hemo-
filtration) in acutely ill patients with AKI [8]. However, 
what potassium concentration or other clinical indica-
tions (e.g., significant ECG changes) should serve as 
triggers for RRT remain debated [8]. However, the lit-
erature does however provide some guidance  [79]. In 
a recent trial, a strategy of delayed RRT (with timing 
of RRT determined by serum creatinine or urine out-
put) ultimately avoided RRT in many patients [80]. Not 
unexpectedly, medical treatment for hyperkalemia was 
more frequent in the delayed group, but the incidence 
of arrhythmias did not differ between groups. Of note, 
patients with potassium > 6, or > 5.5  mmol/L despite 
medical treatment, were excluded, a factor limiting con-
clusions regarding acute therapy in those with the most 
severe hyperkalemia. Another trial evaluated hypertonic 
sodium bicarbonate in critically ill patients with severe 
acidaemia (pH < 7.2). They reported the bicarbonate 
group had a lower serum potassium, less need for RRT, 
and a longer delay to RRT in those patients ultimately 
requiring RRT [48]. Altogether these data suggest that 
medical treatment of hyperkalemia (including hypertonic 
sodium bicarbonate in patients with metabolic acido-
sis) may be safe in critically ill patients with mild hyper-
kalemia. This medical treatment could avoid or delay 
RRT onset in patients with AKI.
Renal replacement therapy and potassium dialysance
Renal replacement therapies (RRT) include diffusive (i.e., 
hemodialysis), convective (i.e., hemofiltration) and mixed 
modalities (e.g., hemodiafiltration) in the acute setting. 
Potassium dialysance refers to the clearance of potassium 
in various RRT modalities. Body potassium dialysance 
and potassium flux depends on the gradient of potas-
sium concentration between plasma and dialysate (or 
infusate using hemofiltration), blood and dialysate flow 
through the circuit, the modality (hemodialysis, hemofil-
tration, hemodiafiltration), and the dialyzer characteris-
tics. Potassium mass transfer on the other side depends 
on treatment time and intracorporeal potassium kinet-
ics (Fig.  4). Since potassium freely and totally diffuses 
throughout the dialyzer membrane, it is rapidly and 
effectively removed during hemodialysis. In the setting 
of high blood and dialysate flow and low dialysate potas-
sium concentration, serum potassium drops within min-
utes of initiation. Since intracorporeal potassium kinetics 
behave as a multi-compartmental model, serum potas-
sium will decrease more slowly after 2 h of hemodialysis 
and rebound after stopping the therapy. Of note, hyper-
osmolarity, or treatments shifting potassium from the 
extracellular to the intracellular space before the dialysis 
session (i.e., β-2 agonists, sodium bicarbonate, insulin, 
glucose), will decrease potassium dialysance.
Continuous RRT, including hemofiltration (i.e., con-
vective technique), is the most frequently used modality 
in the intensive care unit. Using convective techniques, 
flux of potassium through the membrane depends on the 
ultrafiltration rate and the serum potassium level (Fig. 4). 
When combined techniques are used (i.e., hemodiafil-
tration), elimination of potassium depends mostly on 
the diffusive transfer through the membrane. Continu-
ous low flow techniques have a slower decrease in serum 
potassium concentrations, and the serum potassium 
will tend to approach dialysate (with diffuse techniques) 
or infusate concentration (with convective techniques) 
within few hours after initiation without rebound. 
Hemofiltration using mild to high cut-off membranes 
also allows higher myoglobin removal in patients with 
rhabdomyolysis.
RRT will naturally be a second line strategy. In our 
view, the choice of RRT modality will largely depend 
on the available techniques. The efficacy and tolerance 
will however largely rely on RRT prescription. Using 
short high efficiency dialysis (intermittent dialysis) will 
require high blood and dialysate flow to remove sufficient 
amount of potassium (e.g., blood flow 250  mL/min and 
dialysate flow 500 mL/min) allowing rapid drop of serum 
potassium but with a risk a rebound after stopping RRT 
(Fig. 4). Clearance of potassium using continuous hemo-
filtration is proportional to ultrafiltrate rate (Fig. 4). We 
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Fig. 4 Action mechanisms of hypokalemic treatments by intracellular transfer. a Potassium dialysance, flux and plasma kinetic under short high 
efficient hemodilaysis. b Potassium dialysance, flux and plasma kinetic under long low efficient hemodilaysis. c Potassium clearance, flux and 
plasma kinetic under hemofiltration. K potassium, CVVHD continuous venovenous hemodialysis, CVVHF continuous venovenous hemofiltration
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therefore advise a high ultrafiltration rate at the initiation 
of the technique (e.g.,  ≥ 45  mL/kg/h) when using this 
modality. This ultrafiltration rate can be lowered when 
serum potassium is controlled (e.g., 25 mL/kg/h).
Both techniques expose the patient to the risk of sec-
ondary hypokalemia. Importantly, both hyperkalemia 
and a rapid decrease in serum potassium are associ-
ated with cardiac events and sudden death in patients 
with end-stage kidney disease [81, 82]. Long inter-
dialytic periods expose patients to consequences of 
hyperkalemia and cardiac conduction disorders while 
intradialytic periods and postdialytic periods are asso-
ciated to increase cardiac excitability and arrhythmic 
disorders. Rapid decreases in serum potassium using a 
potassium dialysate concentration ≤ 2 mmol/L was asso-
ciated with a doubling of risk of sudden cardiac arrest 
in a recent study [82]. This arrhythmogenic propensity 
of RRT is enhanced by simultaneous combined stresses 
including ischemia (hypovolemia), hypoxia, electro-
lyte changes (calcium, magnesium, citrate, acetate) and 
potential removal of cardiac medications. Studies have 
shown that the frequency of premature ventricular con-
tractions during dialysis is less common when using a 
dialysate potassium concentration of 2.0–3.0  mmol/L, 
compared ≤ 2.0 mmol/L [83]. More recently, Ferrey et al. 
[84] examined the association of dialysate potassium 
concentration with all-cause mortality risk in chronic 
hemodialysis patients. They observed that a dialysate 
potassium concentration of 1  mEq/L was associated 
with higher mortality compared to higher concentra-
tions. Taken altogether, these data suggest using a potas-
sium dialysate concentration ≥ 2.0  mmol/L to avoid a 
too rapid drop in serum potassium using dialysis. Treat-
ment of hyperkalemia using peritoneal dialysis has been 
described anecdotally and appears feasible when alterna-
tives are not readily available [85]. Alternatives to prevent 
rapid and profound drop of serum potassium is to use 
low flow techniques (i.e., continuous hemofiltration, con-
tinuous hemodialysis or slow low efficiency or extended 
dialysis) (Fig. 4) once acute severe hyperkalemia has been 
controlled. Continuous techniques will further largely 
prevent rebound of serum potassium observed after 
intermittent dialysis. Finally, extended or continuous ses-
sion with high flow should be considered in patients with 
ongoing uncontrolled cause of hyperkalemia (i.e., rhab-
domyolysis, tumor lysis syndrome).
Who should be treated for hyperkalemia?
Even though hyperkalemia has been associated with 
mortality in different settings [5], the potential side 
effects of hyperkalemia treatment should not be over-
looked. Tailoring treatment to the patient condition and 
situation might limit the risk of under or over-treating 
hyperkalemia [34].
The evaluation of hyperkalemia should always include 
assessment for the rapid need of membrane stabilization 
treatment (i.e., calcium or hypertonic sodium solutions) 
and should be considered in patients with cardiac con-
duction or rhythm abnormalities (Figs.  1  and 5). When 
the clinical scenario and absence of ECG changes do 
not support the likelihood of hyperkalemia, the potas-
sium measurement should be repeated to exclude facti-
tious hyperkalemia (or pseudo-hyperkalemia). A result 
of kalemia in delocalized biochemistry (i.e., blood gas 
analyzer) could probably be used to detect hyperkalaemia 
and start a treatment in high-risk patients (e.g., patients 
with severe metabolic acidosis, AKI or CKD).
Efficacy and tolerance of treatment may vary widely 
according to the clinical scenario (Table 2). Insulin–glu-
cose infusion appears to be appropriate for severe hyper-
kalemia due to its efficacy and reproducible lowering of 
serum potassium levels, with close serum glucose mon-
itoring (Fig.  5). However, the impact of this regimen in 
critically ill patients with insulin resistance or dysglyce-
mia remains unclear. Hypertonic sodium bicarbonate 
combines fluid loading, cardiac membrane stabilization 
and serum potassium lowering and is most appropriate 
in patients with severe metabolic acidosis, AKI and hypo-
volemia. Aerosolized β-2 agonists are more easily used 
in spontaneously breathing patients and appear to have 
similar efficacy to the insulin–dextrose combination in 
lowering serum potassium. However, the use of β-2 ago-
nists in patients with cardiac hyperexcitability, baseline 
high sympathetic activity or with unstable coronary dis-
ease is potentially associated with severe side effects or 
decreased efficacy. In addition, efficacy in mechanically 
ventilated patients is unknown. Serial serum potassium 
measurements after first-line treatment allow providers 
to assess the initial response and need for a second line 
strategy. RRT is usually required in patients with severe 
AKI with oliguria or anuria who are not expected to rap-
idly recover (e.g., AKI unresponsive to hemodynamic 
optimization, unresponsive to diuretics), in patients with 
end-stage chronic kidney disease admitted for an acute 
condition and in the setting of severe AKI and hyper-
kalemia (i.e.,  > 6.5  mmol/L) and in patients with hyper-
kalemia resistant to medical therapy [8, 34].
Finally, identification and treatment of the cause and 
contributing factors of hyperkalemia should be per-
formed simultaneously. Identification of the cause of AKI 
and rapid correction of contributing factors of AKI may 
allow faster recovery.
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Conclusion
Recognition of hyperkalemia-related ECG changes is 
central in the choice of strategy to treat the patient. 
ECG changes should prompt urgent medical interven-
tion including both cardiac protection and potassium-
lowering treatment. Tailoring treatment of hyperkalemia 
to the patient condition and situation will limit the risks 
of treatments side effects. Efficacy and tolerance remain 
however poorly explored in acute setting. There is a need 
for further research to evaluate both efficacy and side 
effects of different strategies in the acute setting.
Fig. 5 First-line treatment of hyperkalemia. During hyperkalemia with ECG modifications, first-line therapy should consist on cardiomyocyte 
stabilization using calcium salt or hypertonic sodium (red panel), second line therapy on treatment leading to a fast transfer of potassium from 
extracellular to intracellular space using either insulin–glucose i.v, aerosol of β2 agonist and/or sodium bicarbonate (in case of metabolic acidosis 
and hypovolemic patient) depending of the patient’s comorbidities and clinical status. Insulin–glucose is recommended as the first-line treatment 
in severe hyperkalemia (i.e., above 6.5 mmol/L) but close glucose monitoring is mandatory. β2 agonists can be used in spontaneously breathing 
patients but with safety concerns in patients with unstable angina or cardiac failure. Hypertonic sodium bicarbonate should probably be restricted 
to hypovolemic patients with metabolic acidosis (blue panel). Strategies increasing potassium renal excretion decreases the total potassium 
pool (i.e., hemodynamic optimization and correction of acute kidney injury or loop Henle diuretics in patients with fluid overload) (green panel). 
Indications of renal replacement therapy are patients with severe acute kidney injury associated to severe hyperkalemia or persistent hyperkalemia 
despite first-line medical treatment
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Additional file
Additional file 1: Figure S1. Gastrointestinal absorption site of ZS-9, SPS 
and patiromer. The majority of potassium is in the distal gastrointestinal 
(GI) tract (e.g., the colon). Both sodium polystyrene sulfonate (SPS) and 
patiromer are concentration dependent binding (with patiromer being 
better than SPS). Since there is not relatively much potassium in the early 
part of the GI tract, SPS and patiromer have less of an effect because there 
is less for them to bind. Furthermore divalent cation  (Ca2+ and  Mg2+) are 
inadvertently pick up as well. On the contrary, sodium zirconium cyclosili-
cate (ZS9), which is much more attracted to potassium and more specific 
than SPS or patiromer (binding coefficient much higher), that it can bind 
potassium in low concentration environments with less competition with 
divalent cation, so it starts binding earlier in the GI tract.
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